ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients -March 11, 2024 at 08:02 am EDT | MarketScreener

Phase 2b trial of izokibep for hidradenitis suppurativa showed significant clinical improvements, with a third of patients achieving HiSCR100 by week 16. Patients switching from placebo to izokibep at week 16 matched the response speed and magnitude of those starting treatment earlier. Izokibep demonstrated a favorable safety profile and potential for differentiation with higher clinical responses. Long-term data indicated no increased safety risks and further clinical improvements over time.